Next Generation Chemistry Centers for Fusion Oncoproteins (UM1 Clinical Trial Not Allowed)

The summary for the Next Generation Chemistry Centers for Fusion Oncoproteins (UM1 Clinical Trial Not Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Next Generation Chemistry Centers for Fusion Oncoproteins (UM1 Clinical Trial Not Allowed): NCI is forming the Targeting Fusion Oncoproteins in Childhood Cancers (TFCC) Network to advance our understanding of the mechanisms of action of fusion oncoproteins in pediatric cancers and to apply novel chemical strategies for developing targeted therapeutic approaches. This RFA will use the UM1 mechanism to fund Next Generation Chemistry Centers (NGC) for Fusion Oncoproteins that have independent research projects using innovative chemical biology technologies and chemoproteomic approaches to target fusion-driven cancers. The goal of these discovery efforts will be to identify and develop small molecules that effectively disrupt fusion oncoproteins through mechanisms including, but not limited to, inhibiting activities of individual fusion oncoproteins, blocking critical fusion protein interactions, interacting with coding and/or noncoding RNAs required for fusion protein oncogenesis, and selectively inducing fusion protein degradation or degradation of proteins representing critical fusion oncoprotein dependencies. Compounds envisaged to be derived from these efforts may be either at the level of chemical probes and tools to delineate underlying biology, advanced leads to support further optimization to a candidate, or potential drug candidates themselves. In addition to the research proposed in their applications, each NGC Center will be expected to participate in collaborative projects with the U01s and potentially other members of the fusion oncoprotein community. Funding priority will be given to applications that focus on fusion oncoproteins found in tumors that have high risk of treatment failure and for which there has been little progress in identifying targeted agents. Applications focused on high-risk pediatric solid tumors and brain cancers are particularly encouraged. UM1 recipients will meet regularly with U01 grantees funded through the Mechanisms of Fusion-Driven Oncogenesis in Childhood Cancers FOA.

Federal Grant Title:	Next Generation Chemistry Centers for Fusion Oncoproteins (UM1 Clinical Trial Not Allowed)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Education Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-CA-23-037
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.395
CFDA Descriptions:	Information not provided
Current Application Deadline:	November 15th, 2023
Original Application Deadline:	November 15th, 2023
Posted Date:	July 17th, 2023
Creation Date:	July 17th, 2023
Archive Date:	December 21st, 2023
Total Program Funding:
Maximum Federal Grant Award:	$1,500,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	July 17th, 2023

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Link to Full Grant Announcement: https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-037.html
Grant Announcement Contact: NIH Grants Information
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Similar Government Grants: • Specialized Programs of Research Excellence (SPOREs) in Cancer Health Disparities and Mino...; • Cancer Adoptive Cellular Therapy Network (Can-ACT) for Pediatric Cancers (UG3/UH3 Clinical...; • Single Source: Pediatric Early Phase Clinical Trials Network (PEP-CTN; UM1 Clinical Trial ...; • Assay development and screening for discovery of chemical probes, drugs or immunomodulator...; • The Blood and Marrow Transplant Clinical Trials Network - Core Clinical Centers (UG1 Clini...; • Breast and Prostate Cancer Data Quality and Patterns of Care Study; • Consortium Therapeutic Studies of Primary Central Nervous System Malignancies in Adults; • National Cooperative Drug Discovery Groups for Cancer
More Grants from the National Institutes of Health: • NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed); • NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Required); • Safety and Early Efficacy Studies of Psychedelic-Assisted Therapy for Chronic Pain in Olde...; • NIH Pathway to Independence Award (Parent K99/R00 Independent Basic Experimental Studies w...; • Mentored Research Scientist Development Award (Parent K01 Independent Basic Experimental S...